Y Mabs Therapeutics Stock Investor Sentiment

YMAB Stock  USD 4.67  0.06  1.27%   
About 75% of Y MAbs' investor base is looking to short. The analysis of the overall investor sentiment regarding Y mAbs Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Y MAbs' historical and current headlines, can help investors time the market. In addition, many technical investors use Y mAbs Therapeutics stock news signals to limit their universe of possible portfolio assets.

Comfort Level 25

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Y MAbs' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Y mAbs Therapeutics.

YMAB Historical Sentiment

Although Y MAbs' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding YMAB, such as negative comments on social media and news outlets, may cause fear in the market and push Y MAbs' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of YMAB.
  

Y MAbs Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Y MAbs can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Specia...
Yahoo News
over six months ago at simplywall.st         
Institutional investors may overlook Y-mAbs Therapeutics, Inc.s recent US57m market cap drop as long...
Simply Wall St News at Macroaxis
over six months ago at globenewswire.com         
Y-mAbs to Participate in Upcoming Investor Conferences in September
Macroaxis News: globenewswire.com
over six months ago at news.google.com         
Disposition of 50000 shares by Lund-hansen Torben of Y MAbs at 15.37 subject to Rule 16b-3
Google News at Macroaxis
over six months ago at news.google.com         
Insider Selling Y-mAbs Therapeutics, Inc. COO Sells 5,000 Shares of Stock - MarketBeat
Google News at Macroaxis
over six months ago at www.macroaxis.com         
Disposition of 5000 shares by Joris Wilms of Y MAbs at 14.69 subject to Rule 16b-3
Macroaxis News
over six months ago at www.macroaxis.com         
Disposition of 28629 shares by Bo Kruse of Y MAbs at 2.0 subject to Rule 16b-3
Macroaxis News
over six months ago at simplywall.st         
Y-mAbs Therapeutics Second Quarter 2024 Earnings EPS Misses Expectations
Simply Wall St News at Macroaxis
over six months ago at insidermonkey.com         
Y-mAbs Therapeutics, Inc. Q2 2024 Earnings Call Transcript
insidermonkey News
over six months ago at globenewswire.com         
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
Yahoo News
over six months ago at investorplace.com         
YMAB Stock Earnings Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q2 2024
sbwire news
over six months ago at gurufocus.com         
Y-mAbs Therapeutics Inc Q2 2024 Earnings EPS Misses at -0. ...
Gurufocus Stories at Macroaxis
over six months ago at seekingalpha.com         
Y-mAbs Therapeutics GAAP EPS of -0.21 misses by 0.06, revenue of 22.8M misses by 0.22M
seekingalpha News
over six months ago at zacks.com         
Y-mAbs Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
zacks News
Far too much social signal, news, headlines, and media speculation about Y MAbs that are available to investors today. That information is available publicly through YMAB media outlets and privately through word of mouth or via YMAB internal channels. However, regardless of the origin, that massive amount of YMAB data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Y MAbs news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Y MAbs relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Y MAbs' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Y MAbs alpha.

Y MAbs Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
01/06/2025
2
Acquisition by Larocca John of 21500 shares of Y MAbs subject to Rule 16b-3
01/17/2025
3
Y-mAbs Therapeutics, Inc. Receives 20.89 Average Price Target from Analysts - MarketBeat
02/07/2025
4
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March ...
02/20/2025
5
Shareholders in Y-mAbs Therapeutics are in the red if they invested five years ago
02/26/2025
6
Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications
03/03/2025
7
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
03/04/2025
8
Q4 2024 Y-mAbs Therapeutics Inc Earnings Call Transcript
03/05/2025
9
Disposition of 10810 shares by Thomas Gad of Y MAbs at 5.23 subject to Rule 16b-3
03/07/2025

Complementary Tools for YMAB Stock analysis

When running Y MAbs' price analysis, check to measure Y MAbs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Y MAbs is operating at the current time. Most of Y MAbs' value examination focuses on studying past and present price action to predict the probability of Y MAbs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Y MAbs' price. Additionally, you may evaluate how the addition of Y MAbs to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Content Syndication
Quickly integrate customizable finance content to your own investment portal